Immuneering Corporation - Class A — Cash Flow (NASDAQ:IMRX) | MetaTrader

Open full chart

Financials

Overview Relevé Statistics

Quarterly Annual

Cash from operating activities -30.85 M-44.1 M-48.97 M-55 M-45.34 M -45.34 M Cash from investing activities -75.62 M41.83 M7.3 M26.43 M-88.74 M -88.74 M Cash from financing activities 144.26 M19 K28.44 M5.3 M226.58 M 226.58 M Free cash flow -30.91 M-44.84 M-49.31 M-55.08 M-45.49 M -45.49 M

Nouvelles

The 'Unprecedented' Cancer Test Results That Sent Revolution Medicines Flying

3 Best Stocks to Buy Now, 3/10/2026, According to Top Analysts - TipRanks.com

Piper Sandler cuts Immuneering stock price target on launch timing

Oppenheimer réitère sa recommandation sur Immuneering après les progrès du pipeline

Oppenheimer reiterates Immuneering stock rating on pipeline progress

Le directeur commercial d’Immuneering (IMRX) achète des actions pour 24.990€

Immuneering’s (IMRX) chief business officer buys $24,990 in stock

Le directeur d’Immuneering Schall achète des actions pour 101k€

Essai sur le cancer du pancréas d'Immuneering annonce des données de survie encourageantes, mais le cours de l'action baisse | Benzinga France

Marché boursier aujourd'hui : S&P 500, Dow Jones, Nasdaq 100 Futures en baisse - AZZ, Northrop Grumman, Immuneering à l'honneur (MISE À JOUR) | Benzinga France

Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data (NASDAQ:IMRX)

U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.55%